UNSPSC 51151671: Vamicamide

This classification denotes an antimuscarinic agent with the molecular formula C18H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RU10K34QRU, chemically known as 2-pyridineacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-, (r*,r*)-(+-)- but generally known as vamicamide, which bears US NIH Compound Identifier 65967. European Medicines Agency schedules Vamicamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00020MIG.

UNSPSC 51151671 Vamicamide, a Commodity code, nominally addresses a specific pharmaceutical compound, but recent state and local solicitations tagged under this code do not reflect vamicamide procurement — instead, they center on naloxone (opioid antagonist) and drug deactivation systems, and on broader pharmacy benefit program innovation. State and local issuing bodies using this code are acquiring tangible pharmaceutical products and related services to support community health and public health infrastructure, particularly opioid-response and pharmacy-management initiatives. The mix of issuing bodies includes county health departments (Seminole County, Florida) and state health and human services agencies (Texas Health and Human Services Commission), suggesting that the code may be applied inconsistently across jurisdictions or that naloxone and drug-deactivation products are being cataloged under a vamicamide taxonomy entry in state procurement systems.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida released IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor information about direct-to-manufacturer prescription fulfillment models and therapeutic pharmacy programs, with a response deadline of April 3, 2026. The mismatch between the code's stated product name and the actual solicitations suggests either miscoding in the state procurement systems or that the code entry itself requires clarification — a firm pursuing this code should verify the actual commodity scope with the issuing jurisdiction before responding.